Detalhe da pesquisa
1.
Transcriptomic signatures of tumors undergoing T cell attack.
Cancer Immunol Immunother
; 71(3): 553-563, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272988
2.
The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro.
Cancer Immunol Immunother
; 70(6): 1771-1776, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33165629
3.
In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes.
Cancer Immunol Immunother
; 69(11): 2179-2191, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32472369
4.
Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
Br J Cancer
; 120(8): 870, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30890776
5.
Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
Br J Cancer
; 120(4): 424-434, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30718808
6.
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
J Immunother Cancer
; 12(5)2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38782542
7.
First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer.
Front Immunol
; 14: 1122977, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999039
8.
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Oncoimmunology
; 11(1): 2023255, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35036074
9.
Altered Antibody Response to Epstein-Barr Virus in Patients With Rheumatoid Arthritis and Healthy Subjects Predisposed to the Disease. A Twin Study.
Front Immunol
; 12: 650713, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33777048
10.
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens.
Front Immunol
; 12: 705422, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34707600
11.
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Cancer Cell
; 39(12): 1623-1642.e20, 2021 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34739845
12.
CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer.
Sci Rep
; 10(1): 3914, 2020 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32127601
13.
Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer.
Cancers (Basel)
; 12(12)2020 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33352957
14.
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer.
Oncotarget
; 11(22): 2092-2105, 2020 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32547707
15.
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma.
Cancers (Basel)
; 12(11)2020 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33198174
16.
T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Cancer Immunol Res
; 6(2): 222-235, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29301752
17.
Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.
Oncoimmunology
; 7(12): e1502905, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30524900
18.
PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer.
Clin Cancer Res
; 23(19): 5779-5788, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28679768
19.
Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.
Hum Vaccin Immunother
; 11(12): 2790-5, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26308285